Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • AK002: Phase I started

    Allakos Inc., San Carlos, Calif. Product: AK002 Business: Hematology Molecular target: Undisclosed Description: Undisclosed antibody that induces the killing of mast cells and eosinophils Indication: Treat indolent …

    Published on 9/26/2016
  • B244: Phase IIb started

    AOBiome LLC, Cambridge, Mass. Product: B244 Business: Dermatology Molecular target: NA Description: Live strain of the ammonia-oxidizing bacteria (AOB) Nitrosomonas eutropha D23 Indication: Treat mild to moderate acne …

    Published on 9/26/2016
  • BL-8040: Phase IIa started

    Biokine Therapeutics Ltd., Tel Aviv, Israel BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Product: BL-8040 (formerly BKT-140) Business: Cancer Molecular target: CXC chemokine receptor 4 (CXCR4) (NPY3R) …

    Published on 9/26/2016
  • BXQ-350: Phase I started

    Bexion Pharmaceuticals LLC, Cleveland, Ohio Product: BXQ-350 Business: Cancer Molecular target: NA Description: Nanovesicle formulation of lysosomal protein saposin C and the phospholipid dioleoylphosphatidylserine (…

    Published on 9/26/2016
  • CB-1158: Phase I started

    Calithera Biosciences Inc. (NASDAQ:CALA), South San Francisco, Calif. Product: CB-1158 Business: Cancer Molecular target: Arginase 1 (ARG1); Arginase 2 (ARG2) Description: Arginase 1 (ARG1) and ARG2 inhibitor Indication…

    Published on 9/26/2016
  • Cenicriviroc: Phase I started

    Dong-A ST Co. Ltd. (KSE:170900), Seoul, South Korea Tobira Therapeutics Inc. (NASDAQ:TBRA), San Francisco, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Cenicriviroc (formerly TBR-652) …

    Published on 9/26/2016
  • CERC-301: Completed Phase II enrollment

    Cerecor Inc. (NASDAQ:CERC), Baltimore, Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: CERC-301, MK-0657 Business: Neurology Molecular target: NMDA receptor NR2B subtype (GRIN2B) (NR2B) (GluN2B) Description: …

    Published on 9/26/2016
  • EGEN-001: Phase Ib ongoing

    Celsion Corp. (NASDAQ:CLSN; Tel Aviv:CLSN), Lawrenceville, N.J. Product: EGEN-001, GEN-1 Business: Cancer Molecular target: Interleukin-12 (IL-12) Description: IL-12-expressing plasmid formulated with a lipopolymeric …

    Published on 9/26/2016
  • Evogliptin: Phase I started

    Dong-A ST Co. Ltd. (KSE:170900), Seoul, South Korea Tobira Therapeutics Inc. (NASDAQ:TBRA), San Francisco, Calif. Product: Evogliptin (DA-1229) Business: Hepatic Molecular target: Dipeptidyl peptidase-4 (DPP-4) (CD26) …

    Published on 9/26/2016
  • FLX-787: Phase II started

    Flex Pharma Inc. (NASDAQ:FLKS), Boston, Mass. Product: FLX-787 Business: Neurology Molecular target: Transient receptor potential vanilloid 1 (TRPV1) (VR1); Transient receptor potential A1 (TRPA1) Description: Transient…

    Published on 9/26/2016
  • GMI-1271: Phase I started

    GlycoMimetics Inc. (NASDAQ:GLYC), Rockville, Md. Product: GMI-1271 Business: Cancer Molecular target: E selectin (SELE) (CD62E) Description: Inhibitor of E selectin (SELE; CD62E) Indication: Treat refractory multiple …

    Published on 9/26/2016
  • GSK3326595: Phase I started

    Epizyme Inc. (NASDAQ:EPZM), Cambridge, Mass. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK3326595 (formerly EPZ015938) Business: Cancer Molecular target: Protein arginine methyltransferase 5 (PRMT5)…

    Published on 9/26/2016
  • JNJ-63709178: Phase I hold

    Genmab A/S (CSE:GEN), Copenhagen, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: JNJ-63709178 Business: Cancer Molecular target: CD3; Interleukin-3 (IL-3) receptor alpha (CD123) Description: …

    Published on 9/26/2016
  • KD025: Phase II started

    Kadmon Holdings Inc. (NYSE:KDMN), New York, N.Y. Product: KD025 (formerly SLx-2119) Business: Autoimmune Molecular target: Rho-associated coiled-coil containing protein kinase 2 (ROCK2) Description: Oral selective …

    Published on 9/26/2016
  • KD025: Phase IIa started

    Kadmon Holdings Inc. (NYSE:KDMN), New York, N.Y. Product: KD025 (formerly SLx-2119) Business: Transplant Molecular target: Rho-associated coiled-coil containing protein kinase 2 (ROCK2) Description: Oral selective …

    Published on 9/26/2016
  • MRX34: Phase I discontinued

    Marina Biotech Inc. (Pink:MRNA), Bothell, Wash. Mirna Therapeutics Inc. (NASDAQ:MIRN), Austin, Texas Product: MRX34, miR-34 (formerly miR-Rx34) Business: Cancer Molecular target: NA Description: Synthetic mimic of miR-…

    Published on 9/26/2016
  • NP001: Phase II started

    Neuraltus Pharmaceuticals Inc., Palo Alto, Calif. Product: NP001 Business: Neurology Molecular target: NA Description: Small molecule regulator of macrophage activation Indication: Treat amyotrophic lateral sclerosis (…

    Published on 9/26/2016
  • Oral CR845: Phase IIb started

    Cara Therapeutics Inc. (NASDAQ:CARA), Stamford, Conn. Product: Oral CR845 Business: Neurology Molecular target: Kappa opioid receptor (KOR) (OPRK1) Description: Long-acting peripheral kappa opioid receptor (KOR; OPRK1) …

    Published on 9/26/2016
  • Ornithine phenylacetate: Completed Phase IIa enrollment

    Ocera Therapeutics Inc. (NASDAQ:OCRX), Palo Alto, Calif. Product: Ornithine phenylacetate (IV OCR-002) Business: Hepatic Molecular target: NA Description: IV formulation of an ammonia scavenger Indication: Treat acute …

    Published on 9/26/2016
  • Ornithine phenylacetate: Phase I started

    Ocera Therapeutics Inc. (NASDAQ:OCRX), Palo Alto, Calif. Product: Ornithine phenylacetate (oral OCR-002) Business: Hepatic Molecular target: NA Description: Oral formulation of an ammonia scavenger Indication: Prevent …

    Published on 9/26/2016
  • Ribaxamase: Completed Phase IIb enrollment

    Synthetic Biologics Inc. (NYSE-M:SYN), Rockville, Md. Product: Ribaxamase (SYN-004) (formerly P3A) Business: Infectious Molecular target: NA Description: Second-generation, oral beta lactamase (LACTB) that binds with …

    Published on 9/26/2016
  • SB623: Phase II started

    SanBio Co. Ltd. (Tokyo:4592), Tokyo, Japan Product: SB623 Business: Inflammation Molecular target: NA Description: Bone marrow-derived cells that are transfected with a plasmid construct carrying the intracellular …

    Published on 9/26/2016
  • SGN-CD123A: Phase I started

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Product: SGN-CD123A Business: Cancer Molecular target: Interleukin-3 (IL-3) receptor alpha (CD123) Description: Antibody-drug conjugate (ADC) composed of an anti-IL-3 …

    Published on 9/26/2016
  • Subcutaneous XmAb7195: Phase Ib started

    Xencor Inc. (NASDAQ:XNCR), Monrovia, Calif. Product: Subcutaneous XmAb7195 Business: Inflammation Molecular target: Immunoglobulin E (IgE); Fc gamma receptor IIb (FCGR2B) (CD32B) Description: Humanized mAb targeting IgE…

    Published on 9/26/2016
  • Xanomeline plus trospium chloride: Phase I started

    Karuna Pharmaceuticals Inc., Boston, Mass. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Xanomeline plus trospium chloride (LY246708 plus trospium chloride, KarXT) Business: Neurology Molecular target: …

    Published on 9/26/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993